OncoMatch/Clinical Trials/NCT05967416
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
Is NCT05967416 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SIRPant-M for refractory non-hodgkin lymphoma.
Treatment: SIRPant-M — The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: intratumoral injection therapy
Must not have received prior ITI therapy
Cannot have received: autologous stem cell transplant
Exception: within prior 1 month
Must not have received ASCT or treatment with cellular therapy including CAR-T within the prior 1 month
Cannot have received: CAR-T cell therapy
Exception: within prior 1 month
Must not have received ASCT or treatment with cellular therapy including CAR-T within the prior 1 month
Cannot have received: allogeneic stem cell transplant
Exception: within prior 6 months and must have no active graft-versus-host disease (GVHD) or be under active immunosuppression for GVHD
must not have received allogeneic stem cell transplantation within prior 6 months and must have no active graft-versus-host disease (GVHD) or be under active immunosuppression for GVHD
Cannot have received: systemic anti-cancer therapy
Exception: within the past 14 days before start of study cell therapy
Must not have received prior systemic anti-cancer therapy within the past 14 days before start of study cell therapy
Cannot have received: IL-2 therapy
Exception: within the last 6 months
Must not have received IL-2 therapy within the last 6 months
Cannot have received: investigational agent
Exception: within the past 30 days before start of study cell therapy
Must not have received an investigational agent within the past 30 days before start of study cell therapy
Lab requirements
Blood counts
hemoglobin (Hgb) > 8 g/dL, ANC > 500 /mm3, monocyte counts ≥ 200/μL, and platelets > 50,000/µL
Kidney function
Calculated creatinine clearance ≥60 mL/min (Cockcroft-Gault formula)
Liver function
ALT and AST <3× ULN (unless attributed to leukemic involvement or required concomitant medication); Bilirubin ≤1.5×ULN, unless secondary to Gilbert's Syndrome
Cardiac function
AHA class 1 without significant limitation of physical activity
Must have hematologic values as follows: hemoglobin (Hgb) > 8 g/dL, ANC > 500 /mm3, monocyte counts ≥ 200/μL, and platelets > 50,000/µL... ALT and AST <3× ULN (unless attributed to leukemic involvement or required concomitant medication); Calculated creatinine clearance ≥60 mL/min (Cockcroft-Gault formula); Bilirubin ≤1.5×ULN, unless secondary to Gilbert's Syndrome. Cardiac function: Must be American Heart Association (AHA) class 1 without significant limitation of physical activity
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Hackensack University Medical Center · Hackensack, New Jersey
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify